$1M Grant Advances Promising Leukine® Clinical Trial

Dr. Huntington Potter and his team were recently awarded a total of $1 million.
Aug. 3, 2016

Dr. Huntington Potter and his team were recently awarded a total of $1 million over two years from the Alzheimer’s Association to advance the Leukine® trial to further assess the potential of slowing or even stopping the progression of Alzheimer’s disease. Part of the Alzheimer’s Association’s Part the Cloud Challenge on Neuroinflammation initiative, this grant was awarded to speed investigation of new and innovative approaches to Alzheimer’s disease treatment, including those that target neuroinflammation. CU Anschutz was one of four award-winners – along with the Bellvitge Biomedical Research Institute in Spain; the University of California, Davis; and Longeveron, LLC, in Florida. After the initial two-year funding period, the research project showing the most viable translation into advanced clinical trials will receive an additional award of up to $3 million to further therapy development.

Click here to read the rest of the story at UCDenver.edu

About the author

UCHealth is an innovative, nonprofit health system that delivers the highest quality medical care with an excellent patient experience. With 24,000 employees, UCHealth includes 12 acute-care full-service hospitals and hundreds of physicians across Colorado, southern Wyoming and western Nebraska. With University of Colorado Hospital on the Anschutz Medical Campus as its academic anchor and the only adult academic medical center in the region, UCHealth pushes the boundaries of medicine, providing advanced treatments and clinical trials and improving health through innovation.